Citadel Advisors
FTH

Citadel Advisors’s Faeth Therapeutics FTH Stock Holding History

Citadel Advisors’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,886
Closed -$28.3K – 15488
2024
Q4 		$28.3K Sell
2,886
-416
-13% -$4.17K ﹤0.01% 12925
2024
Q3 		$39.5K Buy
3,302
+2,534
+330% +$30.9K ﹤0.01% 12155
2024
Q2 		$9.53K Sell
768
-425
-36% -$8.84K ﹤0.01% 13135
2024
Q1 		$25.1K Sell
1,193
-97
-8% -$1.67K ﹤0.01% 12845
2023
Q4 		$17.9K Buy
+1,290
New +$17.6K ﹤0.01% 12721
2022
Q3 		– Sell
-2,969
Closed -$134K – 13540
2022
Q2 		$134K Buy
+2,969
New +$111K ﹤0.01% 11100
2021
Q4 		– Sell
-6,163
Closed -$1.3M – 14691
2021
Q3 		$1.3M Sell
6,163
-8,020
-57% -$1.46M ﹤0.01% 7466
2021
Q2 		$2.77M Sell
14,183
-20,444
-59% -$5.05M ﹤0.01% 5797
2021
Q1 		$10.1M Buy
+34,627
New +$11.6M ﹤0.01% 2954

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Citadel Advisors's FTH Position: Q1 2025 in Review

Citadel Advisors sold out of Faeth Therapeutics (FTH) in Q1 2025, closing a stake of 2,886 shares — an estimated $28.3K sold.

Citadel Advisors first reported a position in FTH in Q1 2021 and held it in 9 quarters. The position peaked at $10.1M in Q1 2021. 20 funds tracked by Wall St. Rank hold FTH as of Q1 2025.

  • Citadel Advisors reported no remaining Faeth Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 2,886 Faeth Therapeutics shares in Q1 2025, an estimated $28.3K.
  • Citadel Advisors first reported a position in Faeth Therapeutics in Q1 2021 and held it in 9 quarters.
  • Citadel Advisors's Faeth Therapeutics position peaked at $10.1M in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.